SCHEMBL3378362

SCHEMBL3378362

CS(=O)(=O)Nc1ccc(-c2ccc(F)cc2Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.46
SLC22A12 Q96S37 1/20 0.44
KIT P10721 2/20 0.43
GLO1 Q04760 2/20 0.43
PTGS2 P35354 3/20 0.42
ALOX5AP P20292 1/20 0.42
FEN1 P39748 1/20 0.42
BRD4 O60885 1/20 0.41
KIF11 P52732 1/20 0.41
NR3C1 P04150 1/20 0.40
PGR P06401 1/20 0.40
NR3C2 P08235 1/20 0.40
AR P10275 1/20 0.40
ABL1 P00519 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TLR4 O00206 1/20 0.40
CDK1 P06493 1/20 0.40
CDK2 P24941 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16492686 0.88 KMT2A (0.55) KMT2ASLC22A12PTGS2NR3C1NR3C2
SCHEMBL3377558 0.79 PTGS2 (0.50) GLO1PTGS2KIF11
SCHEMBL3376489 0.78 SCN9A (0.56) KMT2APTGS2BRD4KIF11NR3C1
SCHEMBL3378764 0.77 PTGS2 (0.51) KMT2AKITPTGS2KIF11NR3C1
SCHEMBL3375774 0.76 GAA (0.52) KITBRD4KIF11
SCHEMBL4661120 0.75 TRPV1 (0.54) SLC22A12GLO1ALOX5APFEN1KIF11
SCHEMBL3377083 0.74 PTGS2 (0.52) KMT2APTGS2KIF11LMNATP53
SCHEMBL4184733 0.74 TNKS2 (0.47) GLO1ALOX5APFEN1
SCHEMBL3378891 0.73 SLC22A12 (0.52) KMT2ASLC22A12BRD4KIF11NR3C1
SCHEMBL4659924 0.72 KIF11 (0.74) SLC22A12KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KMT2A 3186/4885SLC22A12 716/4885KIT 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.